These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 28104253

  • 1. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
    Morrow SA, Rosehart H, Johnson AM.
    Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
    [Abstract] [Full Text] [Related]

  • 2. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.
    Jensen HB, Nielsen JL, Ravnborg M, Dalgas U, Aagaard P, Stenager E.
    Mult Scler Relat Disord; 2016 Nov; 10():137-144. PubMed ID: 27919481
    [Abstract] [Full Text] [Related]

  • 3. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K, Pelicon K, Ledinek AH, Sega S.
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [Abstract] [Full Text] [Related]

  • 4. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J, ENHANCE study investigators.
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [Abstract] [Full Text] [Related]

  • 5. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
    Potter PJ, Hayes KC, Segal JL, Hsieh JT, Brunnemann SR, Delaney GA, Tierney DS, Mason D.
    J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
    [Abstract] [Full Text] [Related]

  • 6. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B, Filli L, Reuter K, Kapitza S, Lörincz L, Sutter T, Weller D, Farkas M, Easthope CS, Czaplinski A, Weller M, Linnebank M.
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [Abstract] [Full Text] [Related]

  • 7. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
    Cardenas DD, Ditunno JF, Graziani V, McLain AB, Lammertse DP, Potter PJ, Alexander MS, Cohen R, Blight AR.
    Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
    [Abstract] [Full Text] [Related]

  • 8. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR.
    Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
    [Abstract] [Full Text] [Related]

  • 9. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR, Rivey MP, Allington DR.
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [Abstract] [Full Text] [Related]

  • 10. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    Broicher SD, Filli L, Geisseler O, Germann N, Zörner B, Brugger P, Linnebank M.
    J Neurol; 2018 May; 265(5):1016-1025. PubMed ID: 29464379
    [Abstract] [Full Text] [Related]

  • 11. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
    Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, Tofil-Kaluza A, Hovenden M, Mehta LR, Elkins J.
    Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.
    Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, Petzold A, Verma A, Hesterman J, Wattjes MP, Uitdehaag BMJ, van Rijn LJ, Groeneveld GJ.
    CNS Neurosci Ther; 2019 Jun; 25(6):697-703. PubMed ID: 30756475
    [Abstract] [Full Text] [Related]

  • 14. Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail.
    Mavandadi S, Paybast S, Mirzadeh M, Mozhdehipanah H.
    Acta Neurol Belg; 2024 Aug; 124(4):1289-1294. PubMed ID: 38582798
    [Abstract] [Full Text] [Related]

  • 15. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
    Filli L, Werner J, Beyer G, Reuter K, Petersen JA, Weller M, Zörner B, Linnebank M.
    Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Filli L, Zörner B, Kapitza S, Reuter K, Lörincz L, Weller D, Sutter T, Killeen T, Gruber P, Petersen JA, Weller M, Linnebank M.
    Neurology; 2017 Feb 28; 88(9):832-841. PubMed ID: 28148629
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T, Henney HR.
    Clin Ther; 2009 Oct 28; 31(10):2206-14. PubMed ID: 19922891
    [Abstract] [Full Text] [Related]

  • 19. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators.
    Lancet; 2009 Feb 28; 373(9665):732-8. PubMed ID: 19249634
    [Abstract] [Full Text] [Related]

  • 20. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A.
    J Neurol Sci; 2016 Jan 15; 360():102-9. PubMed ID: 26723984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.